{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T04:41:18Z","timestamp":1794631278783,"version":"4.9.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"68","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA189823"],"award-info":[{"award-number":["UG1CA189823"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA189974"],"award-info":[{"award-number":["UG1CA189974"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG1CA189961"],"award-info":[{"award-number":["UG1CA189961"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180822"],"award-info":[{"award-number":["U10CA180822"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NCI Community Oncology Research Program"},{"DOI":"10.13039\/100018047","name":"NRG Oncology","doi-asserted-by":"publisher","award":["UG1CA189867"],"award-info":[{"award-number":["UG1CA189867"]}],"id":[{"id":"10.13039\/100018047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018047","name":"NRG Oncology","doi-asserted-by":"publisher","award":["UG1CA189823"],"award-info":[{"award-number":["UG1CA189823"]}],"id":[{"id":"10.13039\/100018047","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SWOG","award":["UG1CA189974"],"award-info":[{"award-number":["UG1CA189974"]}]},{"DOI":"10.13039\/100026481","name":"ECOG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100026481","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006384","name":"ACRIN","doi-asserted-by":"publisher","award":["UG1CA189828"],"award-info":[{"award-number":["UG1CA189828"]}],"id":[{"id":"10.13039\/100006384","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007154","name":"Wake Forest University","doi-asserted-by":"publisher","award":["UG1CA189824"],"award-info":[{"award-number":["UG1CA189824"]}],"id":[{"id":"10.13039\/100007154","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008091","name":"University of Rochester","doi-asserted-by":"publisher","award":["UG1CA189961"],"award-info":[{"award-number":["UG1CA189961"]}],"id":[{"id":"10.13039\/100008091","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017012","name":"Children\u2019s Oncology Group","doi-asserted-by":"publisher","award":["5UG1CA189955-11"],"award-info":[{"award-number":["5UG1CA189955-11"]}],"id":[{"id":"10.13039\/100017012","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Examining treatment effects in subgroups of patients defined by demographic, genetic, or clinical characteristics is increasingly of interest given the pursuit of personalized medicine and the importance of representation and equity in treatment decisions. The magnitude or even the direction of the treatment effect may vary across subgroups, and these differential treatment effects could have clinical implications. Subgroup analyses require caution in their interpretation, however, because of the high probability of a false-positive or false-negative conclusion. We outline study design and analysis considerations for responsibly investigating and reporting differential treatment effects across subgroups in oncology trials, with examples from the National Cancer Institute\u2019s National Clinical Trials Network and Community Oncology Research Program. Recommendations include ensuring appropriate representation of patients from subgroups of interest, recognizing power and multiplicity limitations, and treating exploratory subgroup analyses as hypothesis generating rather than practice changing.<\/jats:p>","DOI":"10.1093\/jncimonographs\/lgae045","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T08:03:16Z","timestamp":1740384196000},"page":"22-29","source":"Crossref","is-referenced-by-count":4,"title":["Design and analysis considerations for investigating patient subgroups of interest within cancer clinical trials"],"prefix":"10.1093","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5305-6193","authenticated-orcid":false,"given":"Gina L","family":"Mazza","sequence":"first","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic , Scottsdale, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Culakova","sequence":"additional","affiliation":[{"name":"Division of Supportive Care in Cancer, Department of Surgery, University of Rochester Medical Center , Rochester, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2132-9967","authenticated-orcid":false,"given":"Danielle M","family":"Enserro","sequence":"additional","affiliation":[{"name":"NRG Oncology Statistics and Data Management Center , Philadelphia, PA,","place":["United States"]},{"name":"Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center , Buffalo, NY,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J","family":"Dignam","sequence":"additional","affiliation":[{"name":"NRG Oncology Statistics and Data Management Center , Philadelphia, PA,","place":["United States"]},{"name":"Department of Public Health Sciences, University of Chicago , Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M","family":"Unger","sequence":"additional","affiliation":[{"name":"SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"2025022414053142700_lgae045-B1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(05)17709-5","article-title":"Subgroup analysis in randomised controlled trials: importance, indications, and interpretation","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"2025022414053142700_lgae045-B2","author":"National Institutes of Health","year":"1993"},{"key":"2025022414053142700_lgae045-B3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0197-2456(95)00048-8","article-title":"Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993\u2014the perspective of NIH clinical trialists","volume":"16","author":"Freedman","year":"1995","journal-title":"Control Clin Trials"},{"key":"2025022414053142700_lgae045-B4","year":"2001"},{"key":"2025022414053142700_lgae045-B5","year":"2022"},{"key":"2025022414053142700_lgae045-B6","doi-asserted-by":"crossref","first-page":"pkaa034","DOI":"10.1093\/jncics\/pkaa034","article-title":"Representativeness of Black patients in cancer clinical trials sponsored by the National Cancer Institute compared with pharmaceutical companies","volume":"4","author":"Unger","year":"2020","journal-title":"JNCI Cancer Spectr"},{"key":"2025022414053142700_lgae045-B7","year":"2020"},{"key":"2025022414053142700_lgae045-B8","author":"Cancer Therapy Evaluation Program","year":"2022"},{"key":"2025022414053142700_lgae045-B9","doi-asserted-by":"crossref","first-page":"20552076221099997","DOI":"10.1177\/20552076221099997","article-title":"Role of decentralized clinical trials in cancer drug development: results from a survey of oncologists and patients","volume":"8","author":"de las Heras","year":"2022","journal-title":"Digital Health"},{"key":"2025022414053142700_lgae045-B10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/OP.23.00185","article-title":"Sponsor perspectives on the impact of the COVID-19 pandemic on interventional cancer clinical trial protocols and data quality","volume":"19","author":"Unger","year":"2023","journal-title":"J Clin Oncol Oncol Pract"},{"key":"2025022414053142700_lgae045-B11","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1001\/jama.2022.9265","article-title":"Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial","volume":"327","author":"Basch","year":"2022","journal-title":"JAMA"},{"key":"2025022414053142700_lgae045-B12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3322\/caac.21638","article-title":"Older adult participation in cancer clinical trials: a systematic review of barriers and interventions","volume":"71","author":"Sedrak","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025022414053142700_lgae045-B13","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1200\/JCO.2017.73.4186","article-title":"Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015","volume":"35","author":"Jin","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025022414053142700_lgae045-B14","author":"Centers for Disease Control and Prevention","year":"2022"},{"key":"2025022414053142700_lgae045-B15","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.23.01777","article-title":"Impact of broadening trial eligibility criteria on the inclusion of patients with brain metastases in cancer clinical trials: time series analyses for 2012-2022","volume":"42","author":"Xiao","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025022414053142700_lgae045-B16","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1186\/s13063-023-07672-8","article-title":"Randomized phase III trial evaluating motivational interviewing and text interventions to optimize adherence to breast cancer endocrine therapy (Alliance A191901): The GETSET protocol","volume":"24","author":"Ivory","year":"2023","journal-title":"Trials"},{"key":"2025022414053142700_lgae045-B17","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS10615","article-title":"NRG-CC008: A nonrandomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers [SOROCk]","volume":"40","author":"Huh","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025022414053142700_lgae045-B18","author":"U.S. Department of Health and Human Services","year":"2018"},{"key":"2025022414053142700_lgae045-B19","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0197-2456(02)00242-8","article-title":"The method of minimization for allocation to clinical trials: a review","volume":"23","author":"Scott","year":"2002","journal-title":"Control Clin Trials"},{"key":"2025022414053142700_lgae045-B20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jtho.2020.12.008","article-title":"Statistical considerations for subgroup analyses","volume":"16","author":"Wang","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025022414053142700_lgae045-B21","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S0140-6736(00)02039-0","article-title":"Subgroup analysis and other (mis)uses of baseline data in clinical trials","volume":"355","author":"Assmann","year":"2000","journal-title":"Lancet"},{"key":"2025022414053142700_lgae045-B22","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMsr077003","article-title":"Statistics in medicine\u2014reporting of subgroup analyses in clinical trials","volume":"357","author":"Wang","year":"2007","journal-title":"N Engl J Med"},{"key":"2025022414053142700_lgae045-B23","author":"New England Journal of Medicine"},{"key":"2025022414053142700_lgae045-B24","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/JTO.0b013e3181d9009e","article-title":"What a clinician ought to know: subgroup analyses","volume":"5","author":"Barraclough","year":"2010","journal-title":"J Thorac Oncol"},{"key":"2025022414053142700_lgae045-B25","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"key":"2025022414053142700_lgae045-B26","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988","edition":"2nd ed"},{"key":"2025022414053142700_lgae045-B27","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMp068070","article-title":"The challenge of subgroup analyses\u2014reporting without distorting","volume":"354","author":"Lagakos","year":"2006","journal-title":"N Engl J Med"},{"key":"2025022414053142700_lgae045-B28","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1634\/theoncologist.2019-0316","article-title":"Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the Alliance A031203 CABOSUN trial","volume":"24","author":"George","year":"2019","journal-title":"Oncologist"},{"key":"2025022414053142700_lgae045-B29","article-title":"When to adjust for multiplicity in cancer clinical trials","author":"Unger","journal-title":"JNCI Monogr."},{"key":"2025022414053142700_lgae045-B30","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/bmj.311.7016.1356","article-title":"An evidence based approach to individualising treatment","volume":"311","author":"Glasziou","year":"1995","journal-title":"BMJ"},{"key":"2025022414053142700_lgae045-B31","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/jama.298.10.1209","article-title":"Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification","volume":"298","author":"Kent","year":"2007","journal-title":"JAMA"},{"key":"2025022414053142700_lgae045-B32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7326\/M18-3667","article-title":"The Predictive Approaches to Treatment effect Heterogeneity (PATH) statement","volume":"172","author":"Kent","year":"2020","journal-title":"Ann Intern Med"},{"key":"2025022414053142700_lgae045-B33","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1177\/17407745231171897","article-title":"Overall average treatment effects from clinical trials, one-variable-at-a-time subgroup analyses and predictive approaches to heterogeneous treatment effects: Toward a more patient-centered evidence-based medicine","volume":"20","author":"Kent","year":"2023","journal-title":"Clin Trials"},{"key":"2025022414053142700_lgae045-B34","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jama.2023.3576","article-title":"Toward personalizing care: assessing heterogeneity of treatment effects in randomized trials","volume":"329","author":"Dahabreh","year":"2023","journal-title":"JAMA"},{"key":"2025022414053142700_lgae045-B35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/sim.7064","article-title":"Tutorial in biostatistics: Data-driven subgroup identification and analysis in clinical trials","volume":"36","author":"Lipkovich","year":"2017","journal-title":"Stat Med"},{"key":"2025022414053142700_lgae045-B36","first-page":"33","volume-title":"Design and Analysis of Subgroups with Biopharmaceutical Applications Emerging Topics in Statistics and Biostatistics","author":"Dmitrienko","year":"2020"},{"key":"2025022414053142700_lgae045-B37","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/jnci\/djp175","article-title":"Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group","volume":"101","author":"Albain","year":"2009","journal-title":"JNCI"},{"key":"2025022414053142700_lgae045-B38","doi-asserted-by":"crossref","first-page":"e203842","DOI":"10.1001\/jamanetworkopen.2020.3842","article-title":"Association of patient demographic characteristics and insurance status with survival in cancer randomized clinical trials with positive findings","volume":"3","author":"Unger","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025022414053142700_lgae045-B39","author":"National Cancer Institute","year":"2024"},{"key":"2025022414053142700_lgae045-B40","author":"National Institutes of Health","year":"2017"},{"key":"2025022414053142700_lgae045-B41","doi-asserted-by":"crossref","first-page":"c117","DOI":"10.1136\/bmj.c117","article-title":"Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses","volume":"340","author":"Sun","year":"2010","journal-title":"BMJ"},{"key":"2025022414053142700_lgae045-B42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2643-3230.BCD-20-0123","article-title":"Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare","volume":"2","author":"Gormley","year":"2021","journal-title":"Blood Cancer Discov"}],"container-title":["JNCI Monographs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2025\/68\/22\/62053213\/lgae045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2025\/68\/22\/62053213\/lgae045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T14:06:30Z","timestamp":1740405990000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncimono\/article\/2025\/68\/22\/8030358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":42,"journal-issue":{"issue":"68","published-online":{"date-parts":[[2025,2,24]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncimonographs\/lgae045","relation":{},"ISSN":["1052-6773","1745-6614"],"issn-type":[{"value":"1052-6773","type":"print"},{"value":"1745-6614","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,2,24]]}}}